Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jan 15;60(2):275-8.
doi: 10.1093/cid/ciu798. Epub 2014 Oct 13.

Breastfeeding while taking lamivudine or tenofovir disoproxil fumarate: a review of the evidence

Stephan Ehrhardt  1 , Chan Xie  2 , Nan Guo  1 , Kenrad Nelson  3 , Chloe L Thio  4
Affiliations
Review

Breastfeeding while taking lamivudine or tenofovir disoproxil fumarate: a review of the evidence

Stephan Ehrhardt et al. Clin Infect Dis. .

Abstract

Lamivudine and tenofovir disoproxil fumarate (TDF) are both active against hepatitis B virus (HBV). Due to its potency, high genetic barrier to resistance, and safety during pregnancy, TDF may be useful to prevent HBV transmission from mother to child, which is the leading cause of transmission globally. Despite the safety record of lamivudine and TDF in pregnancy, the labels for both of these drugs recommend against their use during breastfeeding. In this review, we discuss the data regarding lamivudine and TDF use during pregnancy and breastfeeding and find that the exposure to the drug is lower from breastfeeding than from in utero exposure. Thus, the data do not support the contraindication to their use during breastfeeding.

Keywords: breastfeeding; hepatitis B; lamivudine; tenofovir.

PubMed Disclaimer

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles